Literature DB >> 9032340

Altered Rous sarcoma virus Gag polyprotein processing and its effects on particle formation.

Y Xiang1, T W Ridky, N K Krishna, J Leis.   

Abstract

Proteolytic processing of the Rous sarcoma virus (RSV) Gag precursor was altered in vivo through the introduction of amino acid substitutions into either the polyprotein cleavage junctions or the PR coding sequence. Single amino acid substitutions (V(P2)S and P(P4)G), which are predicted from in vitro peptide substrate cleavage data to decrease the rate of release of PR from the Gag polyprotein, were placed in the NC portion of the NC-PR junction. These substitutions do not affect the efficiency of release of virus-like particles from COS cells even though recovered particles contain significant amounts of uncleaved Pr76gag in addition to mature viral proteins. Single amino acid substitutions (A(P3)F and S(P1)Y), which increase the rate of PR release from Gag, also do not affect budding of virus-like particles from cells. Substitution of the inefficiently cleaved MA-p2 junction sequence in Gag by eight amino acids from the rapidly cleaved NC-PR sequence resulted in a significant increase in cleavage at the new MA-p2 junction, but again without an effect on budding. However, decreased budding was observed when the A(P3)F or S(P1)Y substitution was included in the NC-PR junction sequence between the MA and p2 proteins. A budding defect was also caused by substitution into Gag of a PR subunit containing three amino acid substitutions (R105P, G106V, and S107N) in the substrate binding pocket that increase the catalytic activity of PR. The defect appears to be the result of premature proteolytic processing that could be rescued by inactivating PR through substitution of a serine for the catalytic aspartic acid residue. This budding defect was also rescued by single amino acid substitutions in the NC-PR cleavage site which decrease the rate of release of PR from Gag. A similar budding defect was caused by replacing the Gag PR with two PR subunits covalently linked by four glycine residues. In contrast to the defect caused by the triply substituted PR, the budding defect observed with the linked PR dimer could not be rescued by NC-PR cleavage site mutations, suggesting that PR dimerization is a limiting step in the maturation process. Overall, these results are consistent with a model in which viral protein maturation occurs after PR subunits are released from the Gag polyprotein.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9032340      PMCID: PMC191297     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  36 in total

Review 1.  The retroviral enzymes.

Authors:  R A Katz; A M Skalka
Journal:  Annu Rev Biochem       Date:  1994       Impact factor: 23.643

2.  Domains upstream of the protease (PR) in human immunodeficiency virus type 1 Gag-Pol influence PR autoprocessing.

Authors:  G Zybarth; C Carter
Journal:  J Virol       Date:  1995-06       Impact factor: 5.103

3.  Proteolytic activity of novel human immunodeficiency virus type 1 proteinase proteins from a precursor with a blocking mutation at the N terminus of the PR domain.

Authors:  G Zybarth; H G Kräusslich; K Partin; C Carter
Journal:  J Virol       Date:  1994-01       Impact factor: 5.103

Review 4.  Structure-based inhibitors of HIV-1 protease.

Authors:  A Wlodawer; J W Erickson
Journal:  Annu Rev Biochem       Date:  1993       Impact factor: 23.643

5.  Differential proteolytic processing leads to multiple forms of the CA protein in avian sarcoma and leukemia viruses.

Authors:  R B Pepinsky; I A Papayannopoulos; E P Chow; N K Krishna; R C Craven; V M Vogt
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

6.  An assembly domain of the Rous sarcoma virus Gag protein required late in budding.

Authors:  J W Wills; C E Cameron; C B Wilson; Y Xiang; R P Bennett; J Leis
Journal:  J Virol       Date:  1994-10       Impact factor: 5.103

7.  Characterization of a small (25-kilodalton) derivative of the Rous sarcoma virus Gag protein competent for particle release.

Authors:  R A Weldon; J W Wills
Journal:  J Virol       Date:  1993-09       Impact factor: 5.103

8.  Mutational analysis of the substrate binding pockets of the Rous sarcoma virus and human immunodeficiency virus-1 proteases.

Authors:  C E Cameron; T W Ridky; S Shulenin; J Leis; I T Weber; T Copeland; A Wlodawer; H Burstein; D Bizub-Bender; A M Skalka
Journal:  J Biol Chem       Date:  1994-04-15       Impact factor: 5.157

9.  Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection.

Authors:  D D Ho; A U Neumann; A S Perelson; W Chen; J M Leonard; M Markowitz
Journal:  Nature       Date:  1995-01-12       Impact factor: 49.962

10.  Self-assembly in vitro of purified CA-NC proteins from Rous sarcoma virus and human immunodeficiency virus type 1.

Authors:  S Campbell; V M Vogt
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

View more
  13 in total

1.  Activation of the Mason-Pfizer monkey virus protease within immature capsids in vitro.

Authors:  S D Parker; E Hunter
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-27       Impact factor: 11.205

2.  Insertion of capsid proteins from nonenveloped viruses into the retroviral budding pathway.

Authors:  N K Krishna; J W Wills
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

3.  Membrane targeting properties of a herpesvirus tegument protein-retrovirus Gag chimera.

Authors:  J B Bowzard; R J Visalli; C B Wilson; J S Loomis; E M Callahan; R J Courtney; J W Wills
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

4.  The PPPY motif of human T-cell leukemia virus type 1 Gag protein is required early in the budding process.

Authors:  Isabelle Le Blanc; Marie-Christine Prévost; Marie-Christine Dokhélar; Arielle R Rosenberg
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

5.  Assembly and processing of human immunodeficiency virus Gag mutants containing a partial replacement of the matrix domain by the viral protease domain.

Authors:  C T Wang; Y C Chou; C C Chiang
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

6.  Development of Rous sarcoma Virus-like Particles Displaying hCC49 scFv for Specific Targeted Drug Delivery to Human Colon Carcinoma Cells.

Authors:  Tatsuya Kato; Megumi Yui; Vipin Kumar Deo; Enoch Y Park
Journal:  Pharm Res       Date:  2015-06-06       Impact factor: 4.200

7.  Particle size determinants in the human immunodeficiency virus type 1 Gag protein.

Authors:  L Garnier; L Ratner; B Rovinski; S X Cao; J W Wills
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

8.  Noninfectious virus-like particles produced by Moloney murine leukemia virus-based retrovirus packaging cells deficient in viral envelope become infectious in the presence of lipofection reagents.

Authors:  S Sharma; F Murai; A Miyanohara; T Friedmann
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-30       Impact factor: 11.205

9.  Genetic determinants of Rous sarcoma virus particle size.

Authors:  N K Krishna; S Campbell; V M Vogt; J W Wills
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

10.  Initial cleavage of the human immunodeficiency virus type 1 GagPol precursor by its activated protease occurs by an intramolecular mechanism.

Authors:  Steven C Pettit; Lorraine E Everitt; Sumana Choudhury; Ben M Dunn; Andrew H Kaplan
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.